30 October 2020

Definitive Healthcare, the leading provider of data, intelligence and analytics on the healthcare market, today announced its acquisition of Monocl, the leading subscription-based provider of medical and scientific expert data and insights.

Monocl delivers deep professional profiles on millions of experts worldwide, to help companies identify and engage industry opinion leaders. Through the transaction, Definitive fortifies its product offerings for life sciences companies and expands its international presence from North America to Europe and Asia.

“Monocl has always been laser focused on delivering critical expert insights through software to provide our clients with a unique competitive and collaborative edge,” said Björn Carlsson, CEO and co-founder of Monocl. “We are thrilled to unite the power of our groundbreaking expert platform with Definitive’s comprehensive and complementary healthcare provider platform and medical claims analytics. This is truly an example of the whole being much greater than the sum of its parts.”

“The acquisition of Monocl brings together two powerful intelligence platforms to provide best-in-class data, analytics and insight that will help biotech and pharmaceutical companies accelerate clinical research and commercialisation of new drugs and therapies,” said Jason Krantz, founder and CEO of Definitive Healthcare. “Monocl shares the Definitive philosophy of providing the highest quality data through an online interface that gives clients the ability to access and analyse real-time information and intelligence.”

Joakim Dal, Partner at GP Bullhound, added: “Björn and his team have put a very powerful application in the hands of Monocl’s customers. The superior user interface and the vast data library makes this a standard for enterprise applications. During our investment period, Monocl has developed at a rapid pace. We look forward to what the combination of these two leading companies can do to support the critical work in the life sciences sector.”

GP Bullhound invested in Monocl in 2019 through GP Bullhound Fund IV, which focuses on growth stage businesses in the software, digital media, marketplaces and fintech sectors. Other investments include Revolut, Slack, Klarna, Unity, RavenPack and Believe.

2020-10-30 19:19 GMT+01

Oakley Capital (“Oakley”) is pleased to announce that it has agreed to acquire WindStar Medical GmbH (“WindStar Medical”) from ProSiebenSat.1 majority-owned NuCom Group.

WindStar Medical is Germany’s leading over-the-counter (“OTC”) consumer healthcare company. The platform, which is expected to generate over €120 million in revenues this year, designs, develops and commercialises branded consumer health and private label products, with a track record of establishing best-in-class medical formulations and brands.

The Consumer Brands segment of WindStar Medical offers a wide range of premium high-growth branded products in Germany, including SOS (wound care / disinfectants), Zirkulin (gastro-intestinal care), GreenDoc (mental wellbeing) and EyeMedica (eye health). WindStar Medical is also a provider of Private Label products to the leading German drug stores and supermarkets, whilst also developing an international distribution footprint through existing and new partners.

WindStar Medical benefits from the long-term structural growth of Germany’s consumer health market. This growth is being driven both by demographic trends, such as an ageing population, and a shift in consumer preferences driven by factors such as increased awareness of physical and mental wellbeing and willingness to prevent illness. Through its investment, Oakley will support the company’s management team as they continue to drive revenue growth, product innovation, digitalisation, as well as identifying opportunities to scale the business through accretive acquisitions.

The investment in WindStar Medical builds on Oakley’s successful track record of investing in leading consumer platforms in the DACH region, including Verivox, Parship Elite and more recently Wishcard Technologies and 7NXT / Gymondo. The business displays the typical Oakley deal characteristics, as it has an asset-light business model, industry-leading operational capabilities, and an attractive growth profile.

October 20, 2020

Leading Dermatology Practice in Mid-Atlantic and Southeast to Expand Footprint and Capabilities

Charlotte, NC (October 20, 2020) – Ridgemont Equity Partners, a middle market private equity investor, today announced the acquisition of Anne Arundel Dermatology Management (“AAD” or the “Company”), a leading provider of medical, surgical and cosmetic dermatological services in the Mid-Atlantic and Southeastern states. AAD has approximately 181 providers across 74 clinics in Maryland, Virginia, Tennessee, North Carolina, and Pennsylvania and is seeking expansion into new geographic markets. The management team at AAD and physician-owners invested alongside Ridgemont in the transaction.

“Ridgemont has been close to the team at Anne Arundel Dermatology for over three years,” said Walker Poole, Partner at Ridgemont. “Given the strong clinical reputation, established presence across the Mid-Atlantic and Southeastern regions, and successful history of practice affiliations, we view AAD as a top-tier dermatological service provider in the US and are very pleased to add the Company to our portfolio.”

“Dermatology is a large and growing sector that remains highly fragmented,” said Dan Harknett, Principal at Ridgemont. “AAD has an excellent group of high quality dermatology providers and a proven management team that is capable of leading a much larger platform – we are excited to support this team and share the next step in the Company’s continued growth.”

“We have experienced tremendous growth across the Anne Arundel platform over the past several years and are proud of the team and infrastructure we have built,” said Scott Mahosky, CEO of AAD. “Our new partners at Ridgemont share the same vision of supporting high quality physicians focused on providing quality care while reducing the providers’ administrative burden. We look forward to partnering with Ridgemont to continue these efforts while increasing our presence in existing markets and expanding into new states.”

Financing for the transaction was provided by Twin Brook Capital Partners, Crescent Direct Lending, First Eagle Alternative Credit, Pathway Capital Management, Northwestern Mutual Investment Management Company, and funds and accounts sub-advised by Churchill Asset Management. Dechert LLP provided legal services to Ridgemont. Robert W. Baird & Co. served as financial advisor to Ridgemont and Coker Capital served as financial advisor to Anne Arundel Dermatology. Financial terms of the transaction were not disclosed.

About Anne Arundel Dermatology

Anne Arundel Dermatology is a leading provider of dermatological services in Maryland, Virginia, Tennessee, North Carolina, and Pennsylvania. Headquartered in Linthicum Heights, Maryland and with 74 locations and 181 providers, AAD provides a comprehensive suite of dermatologic services, offering general dermatology, advanced treatment options for skin cancer and cosmetic procedures. www.aadermatology.com.

About Ridgemont Equity Partners

Ridgemont Equity Partners is a Charlotte-based middle market buyout and growth equity investor. Since 1993, the principals of Ridgemont have invested approximately $4.4 billion. The firm focuses on equity investments up to $250 million in industries in which it has deep expertise, including business and industrial services, energy, healthcare, and technology and telecommunications.